Screener / SEC EDGAR /CIK 0001599298 /10-K filed Feb 23, 2026, compared with Feb 24, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Summit Therapeutics Inc. SMMT

Compare with peers Embed
FY2025 at a glance

Free cash flow down to -$323.6M

XBRL, from each 10-K
Net incomeStatements
-$1.1B from -$221.3M in FY2024
FY2019FY2025
Free cash flowStatements
-$323.6M from -$142.2M in FY2024
FY2019FY2025
EPS (diluted)Statements
$-1.44 from $-0.31 in FY2024
FY2019FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (26)
EPS (ttm)
-1.06
Sales (ttm)
-
Net income (ttm)
-832.7M
Sales growth
-
EPS growth
-
Sales Q/Q
-
Free cash flow
-526.9M
Gross margin
-
Oper. margin
-
Net margin
-
FCF margin
-
R&D / sales
-
Dividend
-
Debt/Eq
-
Curr. ratio
5.99
Cash
150.8M
Op. cash flow (ttm)
-525.2M
Quick ratio
5.99
FCF after stock pay
-1.1B
Goodwill / assets
0.3%
Shares out.
799.8M
Shares Y/Y
+4.1%
Book / share
0.71
Cash / share
0.19

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2019 to FY2024

Each fiscal year from its own 10-K · XBRL

Revenue 0 Net income -221.3M
FY2019 revenue 57.1M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001599298-21-000011 FY2019 net income 10.9M · NetIncomeLoss, 0001599298-21-000011 57.1M FY2019 FY2020 revenue 860K · RevenueFromContractWithCustomerExcludingAssessedTax, 0001599298-22-000147 FY2020 net income -52.7M · NetIncomeLoss, 0001599298-22-000147 860K FY2020 FY2021 revenue 1.8M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001599298-23-000034 FY2021 net income -88.6M · NetIncomeLoss, 0001599298-23-000034 1.8M FY2021 FY2022 revenue 705K · RevenueFromContractWithCustomerExcludingAssessedTax, 0001599298-25-000048 FY2022 net income -78.8M · NetIncomeLoss, 0001599298-25-000048 705K FY2022 FY2023 revenue 0 · RevenueFromContractWithCustomerExcludingAssessedTax, 0001599298-25-000048 FY2023 net income -614.9M · NetIncomeLoss, 0001599298-26-000015 0 FY2023 FY2024 revenue 0 · RevenueFromContractWithCustomerExcludingAssessedTax, 0001599298-25-000048 FY2024 net income -221.3M · NetIncomeLoss, 0001599298-26-000015 0 FY2024

From XBRL in each 10-K. Hover a bar for the line item and filing.

Growth per share, FY2019 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Book value per share -5.1% a year FY2020 $1.14 to FY2025 $0.88, 5 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 -$1.44$0.88-$0.43
Dec 31, 2024 -$0.31$0.54-$0.20
Dec 31, 2023 -$0.99$0.13-$0.12
Dec 31, 2022 -$0.41$0.66-$0.22
Dec 31, 2021 -$0.67$0.63-$0.55
Dec 31, 2020 -$0.76$1.14-$0.70
Jan 31, 2019 $0.63$3.34-$2.05

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $720.3M
  • − All liabilities $92.3M
  • = Net current asset value $628.0M
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $658.9M
  • − Goodwill $2.0M
  • = Tangible book value $656.9M
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

SMMT against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Return on equity
-5.2%18.5%
-147.5%143rd of 144 · median 9.2%
SMMT and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
SMMT Summit Therapeutics Inc.- ----147.5%--
ROIV Roivant Sciences Ltd.$41.1M -71.6%--838.2%-8.6%-81.2%-
IDYA IDEAYA Biosciences, Inc.$36.5M ----38.5%-957.4%-
CRSP CRISPR Therapeutics AG$25.2M -90.6%---27.7%-0.36
CGON CG Oncology, Inc.$6.2M +255%---24.0%-0.00
SRRK Scholar Rock Holding Corp$570K -----1.16
All 162 companies in the group

Profitability

  • Return on equity below 15%
    -147.5%
  • A profit in 1 of 6 years
Net margin, FY2019 to FY2024: 19.0% to -11174.8%

Balance sheet

  • Interest covered less than 5 times
    Operating income is -26.0× interest expense
  • Current assets cover current liabilities
    Current ratio 5.99
Debt / equity at each year end, FY2019 to FY2024: 4.06 to 0.00

Cash and shareholders

  • Free cash flow positive in 0 of 6 years
    −$142.2M last year
  • Share count up over 5 years
    +15.9%
Free cash flow, FY2019 to FY2024: -35.3M to -142.2M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

SMMT's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 7. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue0
FY2019: 57.1MFY2020: 860KFY2021: 1.8MFY2022: 705KFY2023: 0FY2024: 0FY2025: - FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Net income-1.1B
FY2019: 10.9MFY2020: -52.7MFY2021: -88.6MFY2022: -78.8MFY2023: -614.9MFY2024: -221.3MFY2025: -1.1B FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Free cash flow-323.6M
FY2019: -35.3MFY2020: -48.5MFY2021: -72.9MFY2022: -42.2MFY2023: -76.9MFY2024: -142.2MFY2025: -323.6M FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Free cash flow after stock pay-1.1B
FY2019: -41.6MFY2020: -50.3MFY2021: -85.7MFY2022: -54.2MFY2023: -91.0MFY2024: -193.2MFY2025: -1.1B FY2019FY2020FY2021FY2022FY2023FY2024FY2025
EPS (diluted)-1.44
FY2019: 0.63FY2020: -0.76FY2021: -0.67FY2022: -0.41FY2023: -0.99FY2024: -0.31FY2025: -1.44 FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Diluted shares747.7M
FY2019: 17.2MFY2020: 69.5MFY2021: 131.7MFY2022: 193.3MFY2023: 619.6MFY2024: 718.5MFY2025: 747.7M FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Income statement

From EDGAR
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue57.1M860K1.8M705K00-
R&D52.0M53.3M85.4M52.0M59.5M150.8M537.7M
SG&A17.0M19.2M23.6M26.7M29.3M60.2M556.8M
Operating income5.4M-53.2M-86.2M-72.1M-609.6M-226.0M-
Interest expense620K255K242K4.4M16.5M8.7M0
Pretax income9.1M-52.9M-88.6M-78.8M-614.9M-221.3M-1.1B
Income tax-1.8M-213K0-000
Net income10.9M-52.7M-88.6M-78.8M-614.9M-221.3M-1.1B
EPS (diluted)0.63-0.76-0.67-0.41-0.99-0.31-1.44
Diluted shares17.2M69.5M131.7M193.3M619.6M718.5M747.7M
Depreciation & amortization409K302K330K349K198K89K146K
EBITDA5.8M-52.9M-85.9M-71.7M-609.5M-225.9M-
Operating margin9.4%-6185.2%-4764.3%-10225.4%---
Net margin19.0%-6127.6%-4897.8%-11174.8%---
Revenue growth--+110%-61.0%-100%--

Balance sheet

From EDGAR
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash35.2M66.4M71.8M348.6M71.4M104.9M225.3M
Short-term investments---0114.8M307.5M488.2M
Receivables6.1M331K1.5M349K0--
Current assets61.3M87.7M97.3M656.7M189.7M423.8M720.3M
Property & equipment649K725K694K906K204K254K1.1M
Goodwill2.0M2.0M2.0M1.8M1.9M1.9M2.0M
Other intangible assets13.9M11.5M10.4M000-
Total assets79.6M102.5M113.4M664.2M202.9M435.6M751.2M
Accounts payable5.8M6.1M4.4M355K2.7M4.6M20.3M
Current liabilities17.2M19.9M25.6M38.8M20.4M41.7M73.0M
Total debt---514.3M100.0M0-
Total liabilities23.8M23.0M30.1M537.5M125.3M46.8M92.3M
Shareholders' equity57.6M79.5M83.3M126.7M77.7M388.7M658.9M
Retained earnings-130.9M-210.9M-299.5M-378.3M-993.3M-1.2B-2.3B

Cash flow

From EDGAR
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-35.1M-48.1M-72.6M-41.6M-76.8M-142.1M-322.9M
Capital spending157K421K306K624K128K139K657K
Free cash flow-35.3M-48.5M-72.9M-42.2M-76.9M-142.2M-323.6M
Stock-based pay (added back)6.3M1.8M12.8M11.9M14.1M51.0M732.4M
Free cash flow after stock pay-41.6M-50.3M-85.7M-54.2M-91.0M-193.2M-1.1B
Dividends paid00-----
Investing cash flow-331K-421K-306K-624K-587.8M-205.3M-174.3M
Financing cash flow44.5M50.6M77.9M620.2M86.5M381.2M617.5M

Stock-based pay and leases

From EDGAR
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)6.3M1.8M12.8M11.9M14.1M51.0M732.4M
Stock-based pay / revenue11.0%205.3%707.8%1694.8%---
Operating lease cost501K478K785K1.4M2.2M3.5M3.9M
Operating lease cash paid369K488K1.0M1.1M2.2M2.6M3.7M
Right-of-use assets1.4M554K2.8M4.2M5.9M7.1M20.6M
Operating lease liabilities1.3M465K2.8M4.5M6.1M7.2M20.9M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/SMMT/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.